COMPOSITIONS AND METHODS FOR POTENTIATED ACTIVITY OF BIOLOGICALLY ACTIVE MOLECULES
First Claim
1. A composition comprising a first lipid nanoparticle (LNP) vehicle and a second lipid nanoparticle (LNP) vehicle each having size between about 50 nm and about 500 nm, wherein:
- a) each vehicle comprises a cationic lipid, a neutral lipid, and a PEG-lipid;
b) the first LNP vehicle further comprises one or more short interfering nucleic acid (siNA) molecules comprising a sense strand and a complementary antisense strand, each strand having between 15 and 30 nucleotides in length, wherein the antisense strand comprises between 15 and 30 nucleotides that are complementary to a mammalian RNA sequence and the sense strand comprises between 15 and 30 nucleotides of said mammalian RNA sequence; and
c) the second LNP vehicle further comprises one or more carrier molecules comprising a nucleic acid sequence of at least 15 nucleotides that is not complementary to said mammalian RNA sequence;
wherein the lipids of the first LNP vehicles are the same as or different from the second LNP vehicle.
5 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to novel compositions and methods for potentiating the activity of biologically active molecules in conjunction with one or more delivery vehicles and one or more carrier molecules. Specifically, the invention features the use of a carrier molecule in combination with a delivery vehicle and a biologically active molecule of interest to potentiate the activity of the biologically active molecule. The carrier molecule can be biologically inert, inactive, or attenuated; or can alternately be biologically active in the same or different manner than the biologically active molecule of interest. Specifically, the invention features novel particle forming delivery agents including cationic lipids, microparticles, and nanoparticles that are useful for delivering various biologically active molecules to cells in conjunction with a carrier molecule. The invention also features compositions, and methods of use for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity in a subject or organism that are delivered intracellularly in conjunction with a carrier molecule. In various embodiments, the invention relates to novel cationic lipids, microparticles, nanoparticles and transfection agents that effectively transfect or deliver biologically active molecules, such as antibodies (e.g., monoclonal, chimeric, humanized etc.), cholesterol, hormones, antivirals, peptides, proteins, chemotherapeutics, small molecules, vitamins, co-factors, nucleosides, nucleotides, oligonucleotides, enzymatic nucleic acids, antisense nucleic acids, triplex forming oligonucleotides, 2,5-A chimeras, allozymes, aptamers, decoys and analogs thereof, and small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules, to relevant cells and/or tissues, such as in a subject or organism, in conjunction with one or more carrier molecules. Such novel cationic lipids, microparticles, nanoparticles and transfection agents that are used in conjunction with one or more carrier molecules are useful, for example, in providing compositions to prevent, inhibit, or treat diseases, conditions, or traits in a cell, subject or organism.
-
Citations
33 Claims
-
1. A composition comprising a first lipid nanoparticle (LNP) vehicle and a second lipid nanoparticle (LNP) vehicle each having size between about 50 nm and about 500 nm, wherein:
-
a) each vehicle comprises a cationic lipid, a neutral lipid, and a PEG-lipid; b) the first LNP vehicle further comprises one or more short interfering nucleic acid (siNA) molecules comprising a sense strand and a complementary antisense strand, each strand having between 15 and 30 nucleotides in length, wherein the antisense strand comprises between 15 and 30 nucleotides that are complementary to a mammalian RNA sequence and the sense strand comprises between 15 and 30 nucleotides of said mammalian RNA sequence; and c) the second LNP vehicle further comprises one or more carrier molecules comprising a nucleic acid sequence of at least 15 nucleotides that is not complementary to said mammalian RNA sequence; wherein the lipids of the first LNP vehicles are the same as or different from the second LNP vehicle. - View Dependent Claims (2, 3, 4, 5, 6)
-
-
7. (canceled)
-
8. (canceled)
-
9. (canceled)
-
10. (canceled)
-
11. (canceled)
-
12. (canceled)
-
13. A composition comprising a lipid nanoparticle (LNP) vehicle having size between about 50 nm and about 500 nm, wherein:
-
a) the lipid nanoparticle vehicle comprises a cationic lipid, a neutral lipid, and a PEG-lipid; b) the vehicle further comprises one or more short interfering nucleic acid (siNA) molecules comprising a sense strand and a complementary antisense strand, each strand having between 15 and 30 nucleotides in length, wherein the antisense strand comprises between 15 and 30 nucleotides that are complementary to a mammalian RNA sequence, and the sense strand comprises between 15 and 30 nucleotides of said mammalian RNA sequence; c) the vehicle further comprises one or more carrier molecules comprising a nucleic acid sequence of at least 15 nucleotides that is not complementary to said mammalian RNA sequence. - View Dependent Claims (14, 15, 16)
-
-
17. (canceled)
-
18. (canceled)
-
19. (canceled)
-
20. (canceled)
-
21. (canceled)
-
22. (canceled)
-
23. A composition comprising one or more carrier molecules and a lipid nanoparticle (LNP) vehicle having size between about 50 nm and about 500 nm, wherein:
-
a) the lipid nanoparticle vehicle comprises a cationic lipid, a neutral lipid, and a PEG-lipid; and b) the vehicle further comprises one or more short interfering nucleic acid (siNA) molecules comprising a sense strand and a complementary antisense strand, each strand having between 15 and 30 nucleotides in length, wherein the antisense strand comprises between 15 and 30 nucleotides that are complementary to a mammalian RNA sequence, and the sense strand comprises between 15 and 30 nucleotides of said mammalian RNA sequence. - View Dependent Claims (24, 25, 26)
-
-
27. (canceled)
-
28. (canceled)
-
29. (canceled)
-
30. (canceled)
-
31. (canceled)
-
32. (canceled)
-
33. A composition comprising a first lipid nanoparticle (LNP) vehicle and a second lipid nanoparticle (LNP) vehicle each having size between about 50 nm and about 500 nm, wherein:
-
a) each vehicle comprises a cationic lipid, a neutral lipid, and a PEG-lipid; b) the first LNP vehicle further comprises one or more short interfering nucleic acid (siNA) molecules comprising a sense strand and a complementary antisense strand, each strand having between 15 and 30 nucleotides in length, wherein the antisense strand comprises between 15 and 30 nucleotides that are complementary to a mammalian RNA sequence and the sense strand comprises between 15 and 30 nucleotides of said mammalian RNA sequence; and c) the second LNP vehicle further comprises one or more empty carrier molecules; wherein the lipids of the first LNP vehicles are the same as or different from the second LNP vehicle.
-
Specification
-
- Resources
-
Current AssigneeMerck Sharp & Dohme Corporation (Merck & Co., Inc.)
-
Original AssigneeMerck Sharp & Dohme Corporation (Merck & Co., Inc.)
-
InventorsJadhav, Vasant, Shaw, Lucinda, Jensen, Kristi, Vargeese, Chandra, Morrissey, David
-
Application NumberUS12/526,869Publication NumberTime in Patent OfficeDaysField of SearchUS Class Current424/450CPC Class CodesA61K 31/713 Double-stranded nucleic aci...A61K 9/5123 Organic compounds, e.g. fat...A61P 43/00 Drugs for specific purposes...C12N 15/88 using microencapsulation, e...
